|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 23 |
| 2 | Integrated transcriptomic and metabolomic analyses of a wax deficient citrus mutant exhibiting jasmonic acid-mediated defense against fungal pathogens显示文摘Naturally,resistant crop germplasms are important resources for managing the issues of agricultural product safety and environment deterioration.We found a spontaneous mutant of‘Newhall’navel orange(Citrus sinensis Osbeck)(MT)with broad-spectrum protections against fungal pathogens in the orchard,postharvest-storage,and artificial inoculation conditions.To understand the defense mechanism of MT fruit,we constructed a genome-scale metabolic network that integrated metabolome and transcriptome datasets.The coordinated transcriptomic and metabolic data were enriched in two sub-networks,showing the decrease in very long chain fatty acid(by 41.53%)and cuticular wax synthesis(by 81.34%),and increase in the synthesis of jasmonic acid(JA)(by 95.23%)and JA-induced metabolites such as 5-dimethylnobietin(by 28.37%)in MT.Furthermore,cytological and biochemical analyses confirmed that the response to fungal infection in MT was independent of wax deficiency and was correlated with the levels of jasmonates,and the expression of plant defensin gene PDF1.2.Results of exogenous application of MeJA and JA inhibitors such as propyl gallate proved that JA-mediated defense contributes to the strong tolerance against pathogens in MT.Our results indicated that jasmonate biosynthesis and signaling are stimulated by the fatty acid redirection of MT,and participate in the tolerance of pathogenic fungi. | Yizhong He Jingwen Han Runsheng Liu Yuduan Ding Jinqiu Wang Li Sun Xiaoming Yang Yunliu Zeng Weiwei Wen Juan Xu Hongming Zhang Xiang Yan Zhaoxing Chen Zuliang Gu Hong Chen Huanqing Tang Xiuxin Deng Yunjiang Cheng | 2018 | Horticulture Research2018，5，1： | 8 |
| 3 | Size-controlled MoS2 nanodots supported on reduced graphene oxide for hydrogen evolution reaction and sodium-ion batteries显示文摘转变金属 dichalcogenide nanodots (ND ) 收到了可观的兴趣。我们由在 oleylamine 把铝 pentachloride 和 L 半胱氨酸用作先锋为瞬间 2 ND 报导一条灵巧的自底向上的合成线路。有从 2.2 ~ 5.3 nm 的狭窄的尺寸分布的 ND 的合成,被控制反应时间定制。因为它的涂层特征, oleyalmine 导致 ND 的一致性和 monodispersity。而且, ND 综合了有大特定的表面区域提供活跃地点。Graphene 拥有突出的电导率。联合二材料的优点,因为 2D, 0D/2D 材料展出优异电气化学的性能为离子吸附,精力存储,和变换的可渗透的隧道。同样准备的瞬间 2/rGO (~ 2.2 nm ) 显示出 220 mAhroscopy 分析的一个稳定的能力。与另外的报导金属 oxide/CN composites 比较,有 TiO 2 nanoparticles 的 ultrathin CN-NSs 层的强壮的相互作用制止他们的重新叠,哪个导致 234.0 m 2 的一个大特定的表面区域吗? | Weiyi Sun Pan Li Xue Liu Jiajia Shi Hongming Sun Zhanliang Tao Fujun Li Jun Chen | 2017 | Nano Research2017，10，7： | 6 |
| 4 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 5 | Influence of CeO2 loading on structure and catalytic activity for NH3-SCR over TiO2-supported CeO2显示文摘A series of supported CeO2/TiO2 catalysts were prepared to explore the influence of CeO2 loading on these catalysts for the selective catalytic reduction of NO3 by NH3(NH3-SCR).The catalysts were investigated in detail by means of XRD,Raman,H2-TPR,NH3-TPD,XPS,in situ DRIFTS,and NH3-SCR reaction.The activity of the catalyst is closely related to the content of CeO2.When the loading of CeO2 is near the dispersion capacity(1.16 mmol Ce4+/100 m^2 TiO2),the catalytic activity is better.This may be because that the dispersed CeO2 is the active species and the catalyst has appropriate redox property,along with the larger amounts of surface Ce content and surface adsorbed oxygen species.Finally,a possible reaction mechanism via the Langmuir-Hinshelwood(L-H)mechanism is tentatively proposed to further understand the NH3-SCR reaction. | Hongliang Zhang Long Ding Hongming Long Jiaxin Li Wei Tan Jiawei Ji Jingfang Sun Changjin Tang Lin Dong | 2020 | Journal of Rare Earths2020，38，8： | 5 |
| 6 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 3 |
| 7 | Rapid low-temperature synthesis of perovskite/carbon nanocomposites as superior electrocatalysts for oxygen reduction in Zn-air batteries显示文摘 | Zhenhua Yan Hongming Sun Xiang Chen Xiaorui Fu Chengcheng Chen Fangyi Cheng Jun Chen | 2018 | Nano Research2018，11，6： | 2 |
| 8 | Hydrothermal Synthesized Co-Ni3S2 Ultrathin Nanosheets for Efficient and Enhanced Overall Water Splitting显示文摘We used the one-step hydrothennal controlled synthesis method for Co-Ni3S2 ultrathin nanosheets grown directly on nickel foam(NF).The as-synthesized Co-Ni3S2/NF showed eiilianced activities in the hydrogen evolution reaction(HER),oxygen evolution reaction(OER)and better overall water splitting(OWS)efficiency than the iin-doped Ni3S2/NF.the voltage of Co-Ni3S2/NF for OWS was only 1.58 V at the current density of 10 niA/cm^2 and with long time(>30 h)current output during the current-density(i-t)test.The good i-t pertonnance was also observed in both HER and OER processes.Additionally,the Co-Ni3S2/NF showed a large current density(>1A/cm^2)for both HER and OER.Wlien the current densities reached 100 and 1000 mA/cm^2,the required overpotentials tor Co-Ni3S2/NF were 0.35 and 0.75 V for OER and 0.30 and 0.85 V for HER.Therefore,after introducing Co,the activity of Ni3S2-based material was strongly enhanced. | JIAN Juan YUAN Long LI He LIU Huanhuan ZHANG Xinghui SUN Xuejiao YUAN Hongming FENG Shouhua | 2019 | Chemical Research in Chinese Universities2019，35，2： | 2 |
| 9 | Tuning the properties of Ni-based catalyst via La incorporation for efficient hydrogenation of petroleum resin显示文摘The hydrogenation of petroleum resin(PR)is an effective process to prepare high value-added hydrogenated PR(HPR).However,the preparation of non-noble metal-based catalysts with high catalytic activity for PR hydrogenation still remains a challenge.Herein,a La promoted Ni-based catalyst is reported through the thermal reduction of quaternary Ni La Mg Al-layered double hydroxides(Ni La Mg Al-LDHs).The incorporation of La is beneficial to the reduction and stability of Ni particles with reduced particle size,and the increased alkalinity effectively mitigates the breakage of molecular chains of PR.As a result,the La promoted Ni-based catalyst exhibits high catalytic activity and excellent stability for PR hydrogenation.A hydrogenation degree of 95.4%and 96.1%can be achieved for HC_(5)PR and HC_(9) PR with less reduced softening point,respectively.Notably,the hydrogenation degree still maintains at 92.7%even after 100 hours’reaction,much better than that without La incorporation or prepared using conventional impregnation method. | Qunhong Liu Jiangtao Yang Hongwei Zhang Hongming Sun Shuzheng Wu Bingqing Ge Rong Wang Pei Yuan | 2022 | Chinese Journal of Chemical Engineering2022，35，5： | 2 |
| 10 | Advances in antibiotic therapy for infection after the surgical installation of implants to treat internal fractures显示文摘To summarize the advances in antibiotic therapy for infection after the surgical installation of implants to treat internal fractures. Recent studies on antibiotic therapy for infection after the surgical installation of implants to internal fractures were reviewed and analyzed.In general, systematic antibiotics are selected based on the results of bacterial culture. The duration of antibiotic treatment lasts for no more than 4 to 6 weeks. Orally administered and intravenously injected antibiotics have similar efficacies. Orally administered antibiotics exhibit a lower incidence of complications and are less costly than intravenously injected antibiotics. In addition, the efficacy of daptomycin in the treatment of bone infection is problematic. Rifampicin or fluoroquinolone antibiotics should be jointly administered when infection with bacterial biofilms is likely to occur. Calcium sulfate is a typical topically applied antibiotic delivery vehicle that can be completely degraded, with good biocompatibility, bone conduction, and drug release. The rational, systematic, and combined topical application of antibiotics can effectively decrease the recurrence rates of infection after the surgical installation of implants to treat internal fractures and can improve the quality of life of patients. | Yue Sun Ying Liu Hongming Zhu | 2016 | 国际感染病学(电子版)2016，5，3： | 2 |
| 11 | Rice FLOURY ENDOSPERM 18 encodes a pentatricopeptide repeat protein required for 5′ processing of mitochondrial nad5 messenger RNA and endosperm development显示文摘Pentatricopeptide repeat(PPR) proteins, composing one of the largest protein families in plants,are involved in RNA binding and regulation of organelle RNA metabolism at the posttranscriptional level. Although several PPR proteins have been implicated in endosperm development in rice(Oryza sativa), the molecular functions of many PPRs remain obscure. Here, we identified a rice endosperm mutant named floury endosperm 18(flo18) with pleiotropic defects in both reproductive and vegetative development.Map-based cloning and complementation tests showed that FLO18 encodes a mitochondriontargeted P-type PPR protein with 15 PPR motifs.Mitochondrial function was disrupted in the flo18 mutant, as evidenced by decreased assembly of Complex I in the mitochondrial electron transport chain and altered mitochondrial morphology. Loss of FLO18 function resulted in defective 5′-end processing of mitochondrial nad5 transcripts encoding subunit 5 of nicotinamide adenine dinucleotide hydrogenase. These results suggested that FLO18 is involved in 5′-end processing of nad5 messenger RNA and plays an important role in mitochondrial function and endosperm development. | Mingzhou Yu Mingming Wu Yulong Ren Yihua Wang Jingfang Li Cailin Lei Yinglun Sun Xiuhao Bao Hongming Wu Hang Yang Tian Pan Yongfei Wang Ruonan Jing Mengyuan Yan Houda Zhang Lei Zhao Zhichao Zhao Xin Zhang Xiuping Guo Zhijun Cheng Bing Yang Ling Jiang Jianmin Wan | 2021 | Journal of Integrative Plant Biology2021，63，5： | 2 |
| 12 | Molecular diagnosis and treatment of meningiomas:an expert consensus(2022)显示文摘Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations.The fifth edition of the WHO Classification of Tumors of the Central Nervous System(WHO CNS5),published in 2021,introduces major changes that advance the role of molecular diagnostics in meningiomas.To follow the revision of WHO CNS5,this expert consensus statement was formed jointly by the Group of Neuro-Oncology,Society of Neurosurgery,Chinese Medical Association together with neuropathologists and evidence-based experts.The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients. | Jiaojao Deng Lingyang Hua Liuguan Bian Hong Chen Ligang Chen Hongwei Cheng Changwu Dou Dangmurenjiapu Geng Tao Hong Hongming Ji Yugang Jiang Qing Lan Gang Li Zhixiong Liu Songtao Qi Yan Qu Songsheng Shi Xiaochuan Sun Hajun Wang Yongping You Hualin Yu Shuyuan Yue Jianming Zhang Xiaohua Zhang Shuo Wang Ying Mao Ping Zhong Ye Gong Group of Neuro-Oncology Society of Neurosurgery Chinese Medical Association | 2022 | Chinese Medical Journal2022，135，16： | 1 |
| 13 | Con- tinuous test of ilmenite-based oxygen carriers for chemi- cal looping combustion in a dual fluidized bed reactor system 显示文摘 | Bao Jinhua Li Zhenshan Sun Hongming | 2013 | Industrial & Engineering Chemistry Re- search2013，52，14： | 1 |
| 14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 15 | Experimental and Numerical Study of Biomass Flash Pyrolysis in an En- trained Flow Reactor显示文摘 | Sun Shaozeng Tian Hongming Zhao Yijun | 2010 | Bioresource Technology2010，101，10： | 1 |
| 16 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 17 | Experimental study on cyclone air gasification of wood powder 显示文摘 | Shaozeng Sun Yijun Zhao Hongming Tian | 2009 | Bioresource Technology2009，100，： | 1 |
| 18 | Experimental and numerical study of biomass flash pyrolysis in an entrained flow reactor显示文摘 | Sun Shaozeng Tian Hongming Zhao Yijun | 2010 | Bioresource Technology2010，101，10： | 1 |
| 19 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 20 | Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial显示文摘 | Yi-Long Wu Jin Soo Lee Sumitra Thongprasert Chong-Jen Yu Li Zhang Guia Ladrera Vichien Srimuninnimit Virote Sriuranpong Jennifer Sandoval-Tan Yunzhong Zhu Meilin Liao Caicun Zhou Hongming Pan Victor Lee Yuh-Min Chen Yan Sun Benjamin Margono Fatima Fuerte | 2013 | Lancet Oncology2013，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员